Quantification of p38αMAP kinase: A prognostic marker in HNSCC with respect to radiation therapy

Clinica Chimica Acta

Volumn 413, Issue 1-2, 2012, Pages 219-225

  Gill, Kamaldeep ^a   Mohanti, Bidhu Kalyan ^a   Ashraf, Md Saquib ^a   Singh, Abhay Kumar ^a   Dey, Sharmistha ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Head and neck cancer; P38alpha; Prognostic marker; Radiotherapy

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 14;

ADULT; ARTICLE; CANCER RADIOTHERAPY; CANCER STAGING; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE MARKER; DOSIMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIATION DOSE; SQUAMOUS CELL CARCINOMA; SURFACE PLASMON RESONANCE; TREATMENT RESPONSE; WESTERN BLOTTING;

ADULT; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROGNOSIS; SURFACE PLASMON RESONANCE; TUMOR MARKERS, BIOLOGICAL;

EID: 82955163215     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.09.031     Document Type: Article

References (34)

1. Goldblatt E.M., Lee W.H. From bench to bedside; the growing use of translational research in cancer medicine. Am J Transl Res 2010, 2:1-18.
2. Mohanti B.K., Nachiappan P., Pandey R.M., Sharma A., Bahadur S., Thakar A. Analysis of 2167 head and neck cancer patient's management, treatment compliance and outcomes from a regional cancer centre, Delhi, India. J Laryngol Otol 2007, 121:49-56.
3. Junttila M.R., Ala-aho R., Jokilehto T., et al. p38α and p38β mitogen-activated protein kinase isoforms regulate invasion and growth of head and neck squamous carcinoma cells. Oncogene 2007, 26:5267-5279.
4. Chris M.O., Michael N.H., Hooman I., Tonya C.B., Elias R.O., Juan A. p38 Mitogen-activated protein kinase controls NF-kB transcriptional activation and tumour necrosis factor alpha production through RelA phosphorylation mediated by mitogen- and stress-activated protein kinase 1 in response to Borrelia burgdorferi antigens. Infect Immun 2007, 270-277.
5. Mansour S.J., Matten W.T., Hermann A.S., et al. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 1994, 265:966-970.
6. Brunet A., Pages G., Pouyssegur J. Constitutively active mutants of MAP kinase kinase (MEK1) induce growth factor-relaxation and oncogenicity when expressed in fibroblasts. Oncogene 1994, 9:3379-3387.
7. Cowley S., Paterson H., Kemp P., Marshall C.J. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and transformation of NIH3T3 cells. Cell 1994, 77:841-852.
8. Glarakis I.S., Savva S., Spandidos D.A. Activation of ras genes in malignant and premalignant colorectal tumors. Oncol Rep 1998, 5:1451-1454.
9. Webb C.P., Van Aelst L., Wigler M.H., Vande Woude G.F. Signalling pathways in Ras-mediated tumorigenicity and metastasis. Proc Natl Acad Sci U S A 1998, 95:8773-8778.
10. Licato L.L., Keku T.O., Wurzelmann J.I., et al. In vivo activation of mitogen-activated protein kinases in rat intestinal neoplasia. Gastroenterology 1997, 113:1589-1598.
11. Xiao L., Lang W. A dominant role for the c-Jun NH2-terminal kinase in oncogenic ras-induced morphogenic transformation of human lung carcinoma cells. Cancer Res 2000, 60:400-408.
12. Greenberg A.K., Basu S., Hu J., et al. Selective p38 activation in human non-small cell lung cancer. Am J Respir Cell Mol Biol 2002, 26:558-564.
13. Kaugars G.E., Silverman S., Ray A.K., et al. The use of exfoliative cytology for the early diagnosis of oral cancers: is there a role for it in education and private practice?. J Cancer Educ 1998, 13(2):85-90.
14. Otto A. Excitation of non radioactive surface plasmon plasma waves in silver by the method of frustrated total reflection. Z Phys 1968, 216:398-410.
15. Forrer P., Tamaskovic R., Jaussi R. Enzyme-linked immunosorbent assay for measurement of JNK, ERK, and p38 kinase activities. Biol Chem 1998, 379:1101-1111.
16. Taylor W.H. Serum enzymes in the diagnosis of disease. Br J Anaesth 1969, 41:227-234.
17. Anderson N.L., Anderson N.G. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002, 1:845-867.
18. Thadikkaran L., Siegenthaler M.A., Crettaz D., Queloz P.A. Recent advances in blood-related proteomics. Proteomics 2005, 5:3019-3034.
19. Raingeaud J., Gupta S., Rogers J.S., et al. Pro-inflammatory cytokines and environmental stress cause p38 mitogen-activated protein kinase activation by dual phosphorylation on tyrosine and threonine. J Biol Chem 1995, 270:7420-7426.
20. Ben-Levy R., Hooper S., Wilson R., Paterson H.F., Marshall C.J. Nuclear export of the stress-activated protein kinase p38 mediated by its substrate MAPKAP kinase-2. Curr Biol 1998, 8:1049-1057.
21. Ono K., Han J. The p38 signal transduction pathway: activation and function. Cell Signal 2000, 12:1-13.
22. Prendergast G.C., Jaffee E.M. Cancer immunologists and cancer biologists: why we didn't talk then but need to now. Cancer Res 2007, 67:3500-3504.
23. Negrini S., Gorgoulis V.G., Halazonetis T.D. Genomic instability-an evolving hallmark of cancer. Nat Rev Mol Cell Biol 2010, 11:220-228.
24. Weinstein I.B. The origins of human cancer: molecular mechanisms of carcinogenesis and their implications for cancer prevention and treatment: the twenty-seventh GHA Clowes Memorial award lecture. Cancer Res 1988, 48:4135-4143.
25. Silva P., Slevin N.J., Sloan P., Valentine H., Ryder D., Price P., West C.M., Homer J.J. Use of multiple biological markers in radiotherapy-treated head and neck cancer. J Laryngol Otol 2010, 124(6):650-658.
26. Argiris A., Karamouzis M.V., Raben D., Ferris R. Head and neck cancer. Lancet 2008, 371(9625):1695-1709.
27. Buffa F.M., Bentzen S.M., Daley F.M., et al. Molecular marker profiles predict locoregional control of head and neck squamous cell carcinoma in a randomized trial of continuous hyperfractionated accelerated radiotherapy. Cancer Res 2004, 10:3745-3754.
28. Smith B.D., Smith G.L., Carter D., et al. Molecular marker expression in oral and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2001, 127:780-785.
29. Corry J., Peters L.J., Rischin D. Optimising the therapeutic ratio in head and neck cancer. Lancet Oncol 2010, 11:287-291.
30. Abbott D.W., Holt J.T. Mitogen activated protein kinase kinase 2 activation is essential for progression through the G2/M checkpoint arrest in cells exposed to ionizing radiation. Biol Chem 1999, 274:2732-2742.
31. Olson J.M., Hallahan A.R. p38 MAP Kinase: a convergence point in cancer therapy. Trends Mol Med 2004, 10:125-129.
32. Cuenda A., Rousseau S. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 2007, 1773:1358-1375.
33. Kumar P., Miller A.I., Polverini P.J. p38 MAPK mediates γ-irradiation-induced endothelial cell apoptosis, and vascular endothelial growth factor protects endothelial cells through the phosphinositide 3-kinase-Akt-Bcl-2 pathway. J Biol Chem 2004, 41:43352-43360.
34. Losa J.H., Cobo C.P., Viniegra J.G., Lobo V.J.S.-A., Kajal S.R.Y., Sanchez-Prieto R. Role of p38 MAPK in cisplatin-based therapy. Oncogene 2003, 22:3998-4006.